JYMed Peptide is pleased to announce that Hubei JXBio Pharmaceutical Co., Ltd, its peptide API manufacturing site, has received Korean Drug Master File (K-DMF) registration for Teriparatide Acetate from South Korea’s Ministry of Food and Drug Safety (MFDS). The...
Our Blog
IMPORTANT NOTICE: How to Identify Our Official Website and Avoid Fraudulent Websites
To All Our Customers, Partners, and Members of the Public: We have recently become aware of fraudulent websites impersonating our company online. These fake websites have been unlawfully copying our corporate information, business descriptions, and other materials and...
JYMed Peptides Begins Planning for New Production Lines to Expand Peptide API Manufacturing Capacity
Against the backdrop of sustained growth in the global peptide drug industry, and steadily increasing global client demand for GLP-1-class peptides, peptide-drug conjugates (PDCs), peptide CDMO services, and related capabilities, JYMed Peptides (hereinafter referred...
JYMed Peptide: Peptide CDMO – Making Delivery a Certainty
The peptide sector is undergoing a profound transformation. In the early days, the core question from clients was, “Can it be made?” Today, as GLP-1 therapies and other innovative peptide drugs enter large-scale commercialization, pharmaceutical companies are looking...
JYMed Peptide Wraps Up a Successful CPHI China 2026 in Shanghai
CPHI China 2026 in Shanghai has officially come to a close, and what an incredible event it was for the global pharmaceutical community. CPHI China 2026 in Shanghai: A Successful Event for JYMed Peptide Over three dynamic days, thousands of pharma professionals,...
April-May 2026: Key News in GLP-1 & Peptide Drugs
May 29 | 1. CSPC enters a $18.5 billion global licensing deal with AstraZeneca for peptide platform (including GLP-1 pipeline) Key Highlights: The deal comprises an upfront payment of $1.2 billion and a total potential value of up to $18.5 billion, setting a new...
Welcome Dr. Beatriz G. de la Torre
We are pleased to announce that Dr. Beatriz G. de la Torre has joined JYMed Peptide as Principal Scientific Advisor.Dr. de la Torre has spent over three decades working at the intersection of peptide chemistry and biomedical research, with academic and research...
Welcome, Professor Albericio.
We are pleased to announce that Professor Fernando Albericio has joined JYMed Peptide as Chief Scientific Advisor.It is a privilege to welcome him to the team. Internationally recognized for his extensive contributions to peptide chemistry, including solid-phase...
Happy Labor Day!
Behind every peptide project, there are people making the work possible.From research and production to quality, operations, and customer support, Labor Day is the perfect time to recognize the teams whose dedication makes everything possible, every day.Happy Labor...








